Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Southern Research opens new biotech centre in Alabama
This new facility is part of Southern Research’s ongoing work in human health and biomedical threat research. The $98m facility located at corner of Richard Arrington Jr. Boulevard
This new facility is part of Southern Research’s ongoing work in human health and biomedical threat research. The $98m facility located at corner of Richard Arrington Jr. Boulevard
Iron deficiency anaemia (IDA) is a common complication in chronic kidney disease, and is linked with increased cardiovascular risks and mortality. Viatris’ Iron Sucrose Injection is an intravenous
Vonaprument, formerly known as ANX007, is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation. It has secured Priority
This acquisition expands Intas and Accord’s biosimilar portfolio approved by the FDA and expedites their growth in the global market. With the acquisition, Intas’ US speciality business Accord
CTx-1301 is an extended-release tablet formulation designed for fast onset, all-day efficacy, and a smooth pharmacokinetic profile with a single dose. Cingulate anticipates learning whether the NDA has
The approved drug is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults aged 18 years and above, as well as children between six to
The new facility will help Minaris support its worldwide cell and gene therapy growth. It is designed to facilitate the technology transfer of commercial advanced therapies into Europe.
VT3989 is a transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor to target the Hippo pathway by inhibiting the palmitoylation of TEAD protein family members. Vivace Therapeutics president and
This collaboration is said to result in a “scalable” cGMP production process for DTx’s AAV-based gene therapy candidate targeting open angle glaucoma. As part of this partnership, Northway
This approval follows the previous US Food and Drug Administration (FDA) recognitions, including orphan drug and fast track designations awarded in April 2024 and December 2023 to CAN-2409